FDA Will Increase Financial Disclosure Requirements For Employees
This article was originally published in The Pink Sheet Daily
Move follows the decision to have center directors vet employees’ consulting arrangements. Agency-wide review of outside activity requests finds no further conflicts beyond a situation at CBER that was questioned by the House Energy & Commerce Committee.
You may also be interested in...
Activities had been approved at lower levels, but the interim policy – issued following questions about behavior of NIH scientists – escalates the oversight. All outside activities by FDA employees will be reviewed as part of the development of a final policy.
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.